CAR T-cell therapy is typically considered when myeloma becomes resistant to other treatments (refractory) or returns after treatment (relapsed). While it has shown promising results for many people with hard-to-treat myeloma, it's important to understand that it doesn't work for everyone, and cancer can sometimes return Show Full Answer
CAR T-cell therapy is typically considered when myeloma becomes resistant to other treatments (refractory) or returns after treatment (relapsed). While it has shown promising results for many people with hard-to-treat myeloma, it's important to understand that it doesn't work for everyone, and cancer can sometimes return after treatment.
The treatment requires:
• Collecting your T-cells
• Genetic modification in a lab
• Returning modified cells to your body
• Close monitoring at a certified treatment center
• Staying near the treatment facility for up to a month after treatment Since CAR T-cell therapy isn't available in Manitoba, you would need to consider:
• Travel and accommodation costs
• Time away from home/work
• Support system availability at the treatment location
• Potential side effects that require specialized care
It's recommended to discuss these factors with your healthcare team to weigh the benefits of CAR T-cell therapy against your current DRVD treatment option, taking into account your specific condition, treatment history, and personal circumstances.
September 1, 2025
Join
Your Privacy Choices
